echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > FDA Approves Innovative Imaging Drug to Help Surgeons "Illuminate" Tumors

    FDA Approves Innovative Imaging Drug to Help Surgeons "Illuminate" Tumors

    • Last Update: 2022-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On Target Laboratories announced today that the U.


    Cytoreductive surgery is a common treatment for ovarian cancer, but studies have found that even in patients who received optimal cytoreductive surgery, 40% of patients had measurable findings on imaging tests 30 days after surgery.


    Cytalux is a fluorescent imaging agent that binds to the folate receptor, which is overexpressed in most epithelial ovarian cancers


    References:

    [1] On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During Surgery.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.